Show simple item record

dc.contributor.authorSAHIN, K
dc.contributor.authorSAHIN, F
dc.contributor.authorORHAN, C
dc.contributor.authorKILIC, U
dc.contributor.authorTUZCU, M
dc.contributor.authorKUCUK, O
dc.contributor.authorBASAK, N
dc.contributor.authorElibol-Can, BİRSEN
dc.contributor.authorKILIC, ERDEM
dc.date.accessioned2019-10-05T21:58:35Z
dc.date.available2019-10-05T21:58:35Z
dc.date.issued2015-01-26
dc.identifier
dc.identifier.urihttps://hdl.handle.net/20.500.12645/8591
dc.description.abstractCisplatin is one of the effective chemotherapeutics in the treatment of several types of cancers. However, in addition to the efforts against to its toxicity, the amelioration of cisplatin sensitivity is an important point in treatment of cervical cancer. To do so, additional substances such as epigallocatechin gallate (EGCG), a polyphenol in green tea, have been used in combination with chemotherapeutics. We aimed to investigate the possible molecular pathways to potentiate cervical cancer cell (HeLa) growth inhibition by combination therapy of cisplatin and EGCG. HeLa cells were treated with EGCG (25µM), cisplatin (250 nM), and their combination for 24 h. Cell viability was determined by MTS Assay. We analyzed the expressions of NF-κB p65, COX-2, Nrf2, HO-1, p-mTOR, p-p70S6K1, p-4E-BP1, and p-Akt byWestern blot analysis. Herein, we have demonstrated that EGCG works synergistic with cisplatin in inhibiting growth of cervical cancer cells. EGCG improved efficacy of cisplatin treatment in HeLa cells by regulating NFκB p65, COX-2, p-Akt, and p-mTOR pathways, whereas it increased the expression levels of Nrf2/HO-1 in combined therapy. Our observations revealed that EGCG increases the sensitizen
dc.language.isoen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.subjectKILIC U., SAHIN K., TUZCU M., BASAK N., ORHAN C., Elibol-Can B., KILIC E., SAHIN F., KUCUK O., -Enhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate.-, Frontiers in nutrition, cilt.1, ss.28, 2015
dc.titleEnhancement of Cisplatin sensitivity in human cervical cancer: epigallocatechin-3-gallate.
dc.typeArticle
local.avesis.response8467
local.article.journalnameJournal of Multidisciplinary Research
dc.identifier.doi10.3389/fnut.2014.00028
dc.identifier.pubmed25988128
local.publication.isinternational1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record